Skip to main content
Premium Trial:

Request an Annual Quote

Celera Losses and Revenues Fall in Third Quarter

Celera Genomics cut its losses by almost half but also saw its revenues fall by a third as the company issued its third quarter 2003 financial results today.


The Rockville, Md.-based firm reported a net loss of $26.7 million for the quarter, compared to a net loss of $49.5 million for the year ago quarter. The company had revenues of $20.3 million compared to $30.5 million for the year-ago period and cited its decision not to pursue additional sequencing service business as a primary reason for the drop.


The company took a $15.1 million non-cash charge for its investment in Discovery Partners International, based on the impairment of goodwill and long-term assets, a charge that amounted to $0.13 a share of Celera’s third-quarter net loss of $0.37 a share.


The company’s third-quarter research and development expenses were $27 million, compared to $37.6 million in the third quarter of 2002, based, the company said, on the wind down of the research phase of the Applera Genomics Initiative and programs eliminated in a restructuring in June.


The firsm reported cash and short-term investments of $824 million.
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.